Werewolf Therapeutics stock steadies as investors weigh recent losses and biotech outlook

Published on 09/18/2026 at 18:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Werewolf Therapeutics stock trades below 1 dollar as of September 18, 2026, reflecting a modest gain over recent weeks but heavy losses versus its 52-week high. The biotech’s valuation near 47 million dollars keeps risk high while leaving room for upside if future trial data deliver.

HOWL, US4433141076, Illustration mit AI erstellt.

Werewolf Therapeutics, Inc. stock (ISIN US4433141076) is trading just under the 1 dollar mark as of September 18, 2026, leaving the biotech company valued at around 47.3 million dollars and far below its recent 52-week high level that was more than double the current price.

Stock trades under 1 dollar with constrained valuation

According to finance data summarized by a major portal on September 18, 2026, Werewolf Therapeutics stock (ticker HOWL) last changed hands at around 0.97 dollars on its primary listing in the United States, with the market capitalization reported at approximately 47.292 million dollars as of that date.

A recent performance overview from a German-language stock site dated September 17, 2026 describes the Werewolf Therapeutics share price near 0.96 dollars and highlights a yearly performance of about plus 52.55 percent, while noting that the stock still trades roughly 55.83 percent below its 52-week high and around 225.30 percent above its 52-week low.

Price performance highlights risk-reward profile

The same performance snapshot points out that Werewolf Therapeutics stock gained roughly 131.41 percent over the 30 days to September 18, 2026, but still shows a negative performance of about 33.82 percent over the last 12 months, illustrating the high volatility typical of early-stage biotechnology shares.

For investors, this combination of a plus-52.55 percent yearly gain alongside a still-large 55.83 percent distance to the 52-week high suggests that the stock has rebounded from extreme lows yet remains deeply discounted versus prior peaks, underlining both residual downside risk and potential upside if the company’s clinical pipeline produces positive data.

Analyst sentiment and speculative nature

The German-language overview also cites aggregated analyst opinions, stating that roughly 67 percent of covering analysts rate Werewolf Therapeutics stock as Strong Buy and about 34 percent as Buy, implying an overall positive stance despite the share price volatility and the relatively small market capitalization for a listed biotech.

Because Werewolf Therapeutics focuses on drug development, fundamental figures such as revenue and earnings are likely still dominated by research and development spending and limited product sales, meaning that near-term valuation hinges more on clinical milestones and funding conditions than on traditional profitability metrics.

Stock remains a speculative biotech play

Given the current price level of about 0.97 dollars and the small market capitalization near 47.3 million dollars as of September 18, 2026, Werewolf Therapeutics stock represents a speculative investment where modest changes in sentiment around trial progress or financing could move the share price significantly within the established 52-week range.